Lonza Group Ltd (LZAGF)
| Previous close | 842.00 |
| Open | 826.71 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 803.45 - 826.71 |
| 52-week range | 558.29 - 852.25 |
| Volume | 121 |
| Avg. volume | 164 |
| Market cap | 59.772B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 77.60 |
| EPS (TTM) | 10.35 |
| Earnings date | N/A |
| Forward dividend & yield | 3.32 (0.40%) |
| Ex-dividend date | 10 May 2021 |
| 1y target est | N/A |
- Investing.com
Moderna Slips As Issues At Partners Delay Overseas Release Of Shots
By Dhirendra Tripathi
- Reuters
Vaccine business helps Lonza lift 2021 sales outlook
ZURICH (Reuters) -Swiss contract drugmaker Lonza raised its 2021 outlook on Friday after booming business making ingredients for COVID-19 vaccines and strong growth elsewhere helped it beat analysts' expectations during the first half of the year. "In the prior year we provided an estimate for how much we expected from Moderna sales for 2021...the number is much higher given our ability to increase output at our existing facilities," Chief Financial Officer Rodolfo Savitzky told reporters. Its previous guidance had been for sales growth in the low double-digit range.
- EQS Group
Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin
Lonza Group AG / Key word(s): Half Year Results23-Jul-2021 / 07:01 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad Hoc Release Pursuant to Art. 53 Listing Rules In H1 2021, Lonza continued its strong performance with 14.7%1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19 Continued focus on growth CAPEX investments, supported by strong business pipeline Expanded collaboratio
